glp-1 news nov 2025 ISPOR 2025: Exploring reasons for discontinuation GLP-1 Pipeline Update: November 2025

Opportunities for Retail With the shift in consumer behaviors due to GLP-1 drugs, there has been a significant impact on purchasing patterns, thus influencing retailers

What people complain about: Slow titration is a major complaint

At Lite Medical, we approach obesity as a metabolic condition, not a character flaw

From actors to athletes, the world cant seem to get enough of this miracle drug. This insatiable appetite has ignited a heated debate surrounding safety and ethics

As of 2026, retatrutide holds no MHRA (Medicines and Healthcare products Regulatory Agency) marketing authorisation and is classed as an unlicensed investigational peptide in the UK [1][6]

$118.00 9 in stock 9 in stock This product is intended for laboratory research use only